SE9102808L - Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner - Google Patents

Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner

Info

Publication number
SE9102808L
SE9102808L SE9102808A SE9102808A SE9102808L SE 9102808 L SE9102808 L SE 9102808L SE 9102808 A SE9102808 A SE 9102808A SE 9102808 A SE9102808 A SE 9102808A SE 9102808 L SE9102808 L SE 9102808L
Authority
SE
Sweden
Prior art keywords
ige
vaccine
pct
mediated
antibodies
Prior art date
Application number
SE9102808A
Other languages
English (en)
Swedish (sv)
Other versions
SE9102808D0 (sv
Inventor
Lars T Hellman
Original Assignee
Lars T Hellman Inst F Immunolo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20383848&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9102808(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lars T Hellman Inst F Immunolo filed Critical Lars T Hellman Inst F Immunolo
Priority to SE9102808A priority Critical patent/SE9102808L/xx
Publication of SE9102808D0 publication Critical patent/SE9102808D0/xx
Priority to EP92920757A priority patent/EP0666760B2/en
Priority to US08/196,227 priority patent/US5653980A/en
Priority to CA002117193A priority patent/CA2117193C/en
Priority to AU26765/92A priority patent/AU677573B2/en
Priority to DE69230733T priority patent/DE69230733T3/de
Priority to AT92920757T priority patent/ATE189960T1/de
Priority to DK92920757T priority patent/DK0666760T4/da
Priority to ES92920757T priority patent/ES2144424T5/es
Priority to JP50558293A priority patent/JP3583421B2/ja
Priority to PCT/SE1992/000673 priority patent/WO1993005810A1/en
Priority to RU94020409A priority patent/RU2120805C1/ru
Priority to KR1019940700753A priority patent/KR100263359B1/ko
Priority to HU9400845A priority patent/HU218899B/hu
Publication of SE9102808L publication Critical patent/SE9102808L/xx
Priority to FI941193A priority patent/FI107880B/fi
Priority to NO19941096A priority patent/NO319856B1/no
Priority to GR20000400955T priority patent/GR3033272T3/el
Priority to JP2004084530A priority patent/JP2004231663A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/805—Drug, bio-affecting and body treating compositions involving IgE or IgD
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/862—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgE or IgD
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SE9102808A 1991-09-26 1991-09-26 Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner SE9102808L (sv)

Priority Applications (18)

Application Number Priority Date Filing Date Title
SE9102808A SE9102808L (sv) 1991-09-26 1991-09-26 Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
KR1019940700753A KR100263359B1 (ko) 1991-09-26 1992-09-25 IgE 관련 알레르기 반응의 치료용 IgE의 입실론 사슬의 정상부로 구성된 백신
HU9400845A HU218899B (hu) 1991-09-26 1992-09-25 Eljárás IgE által közvetített allergiás reakciók szimptómáinak enyhítésére vagy indukciójának meggátlására használható vakcina előállítására
DK92920757T DK0666760T4 (da) 1991-09-26 1992-09-25 Vaccine som omfatter en del af den konstante region af IgE til behandling af IgE-medierede allergiske reaktioner
PCT/SE1992/000673 WO1993005810A1 (en) 1991-09-26 1992-09-25 VACCINE COMPRISING PART OF CONSTANT REGION OF IgE FOR TREATMENT OF IgE-MEDIATED ALLERGIC REACTIONS
CA002117193A CA2117193C (en) 1991-09-26 1992-09-25 Vaccine comprising part of constant region of ige for treatment of ige-medicated allergic reactions
AU26765/92A AU677573B2 (en) 1991-09-26 1992-09-25 Vaccine comprising part of constant region of IgE for treatment of IgE-mediated allergic reactions
DE69230733T DE69230733T3 (de) 1991-09-26 1992-09-25 Teil der konstanten region von ige enthaltender impfstoff zur behandlung ige-induzierter allergischer reaktionen
AT92920757T ATE189960T1 (de) 1991-09-26 1992-09-25 Teil der konstanten region von ige enthaltender impfstoff zur behandlung ige-induzierter allergischer reaktionen
EP92920757A EP0666760B2 (en) 1991-09-26 1992-09-25 VACCINE COMPRISING PART OF CONSTANT REGION OF IgE FOR TREATMENT OF IgE-MEDIATED ALLERGIC REACTIONS
ES92920757T ES2144424T5 (es) 1991-09-26 1992-09-25 Vacuna que comprende parte de la region constante de ige para el tratamiento de reacciones alergicas inducidas por ige.
JP50558293A JP3583421B2 (ja) 1991-09-26 1992-09-25 ＩｇＥの不変部の一部を含有するＩｇＥ媒介アレルギー反応治療用ワクチン
US08/196,227 US5653980A (en) 1991-09-26 1992-09-25 Vaccine comprising part of constant region of IgE for treatment of IgE-mediated allergic reactions
RU94020409A RU2120805C1 (ru) 1991-09-26 1992-09-25 Вакцина, обладающая способностью вызывать иммунный ответ против собственного jge организма, способ получения вакцины и способ иммунизации млекопитающего против опосредуемых jge аллергических реакций
FI941193A FI107880B (fi) 1991-09-26 1994-03-14 Menetelmä IgE-välitteisten yliherkkyysreaktioiden hoitamiseksi tarkoitetun rokotteen, joka sisältää osan IgE:n vakioalueesta, valmistamiseksi
NO19941096A NO319856B1 (no) 1991-09-26 1994-03-25 Vaksine for a lindre symptomene ved, eller forhindre inntreden av,IgE-formidlede,allergiske reaksjoner hos et pattedyr,samt anvendelse av aminosyresekvensen fra de konstante CH2-CH3-domener i epsilonkjeden for fremstilling av en vaksine mot IgE-formidlede allergiske reaksjoner.
GR20000400955T GR3033272T3 (en) 1991-09-26 2000-04-19 VACCINE COMPRISING PART OF CONSTANT REGION OF IgE FOR TREATMENT OF IgE-MEDIATED ALLERGIC REACTIONS.
JP2004084530A JP2004231663A (ja) 1991-09-26 2004-03-23 ＩｇＥの不変部の一部を含有するＩｇＥ媒介アレルギー反応治療用ワクチン

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9102808A SE9102808L (sv) 1991-09-26 1991-09-26 Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner

Publications (2)

Publication Number Publication Date
SE9102808D0 SE9102808D0 (sv) 1991-09-26
SE9102808L true SE9102808L (sv) 1993-03-27

Family

ID=20383848

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9102808A SE9102808L (sv) 1991-09-26 1991-09-26 Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner

Country Status (16)

Country Link
US (1) US5653980A (ja)
EP (1) EP0666760B2 (ja)
JP (2) JP3583421B2 (ja)
KR (1) KR100263359B1 (ja)
AT (1) ATE189960T1 (ja)
AU (1) AU677573B2 (ja)
CA (1) CA2117193C (ja)
DE (1) DE69230733T3 (ja)
DK (1) DK0666760T4 (ja)
ES (1) ES2144424T5 (ja)
FI (1) FI107880B (ja)
GR (1) GR3033272T3 (ja)
HU (1) HU218899B (ja)
RU (1) RU2120805C1 (ja)
SE (1) SE9102808L (ja)
WO (1) WO1993005810A1 (ja)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU707083B2 (en) * 1993-08-26 1999-07-01 Bavarian Nordic Inc. Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
WO1995019181A1 (en) * 1994-01-18 1995-07-20 Genentech, Inc. A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS
FR2715304B1 (fr) * 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Vaccin anti-allergique.
IL125590A (en) * 1996-03-01 2001-08-26 Novartis Ag Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
RU2241715C2 (ru) * 1997-04-15 2004-12-10 Фармекса А/С МОДИФИЦИРОВАННАЯ МОЛЕКУЛА ФНОα ЧЕЛОВЕКА, СПОСОБНАЯ ИНДУЦИРОВАТЬ ОБРАЗОВАНИЕ НЕЙТРАЛИЗУЮЩИХ АНТИТЕЛ К ЧЕЛОВЕЧЕСКОМУ ФНОα, ДНК, ЕЕ КОДИРУЮЩАЯ, ВЕКТОР (ВАРИАНТЫ), СПОСОБ ПОЛУЧЕНИЯ, ВАКЦИНА ПРОТИВ ФНОα (ВАРИАНТЫ), СПОСОБ ТЕСТИРОВАНИЯ НА ПРИСУТСТВИЕ ФНОα, СПОСОБ ТЕСТИРОВАНИЯ ЖИДКОСТЕЙ ТЕЛА ЧЕЛОВЕКА, СПОСОБ ДИАГНОСТИКИ, СПОСОБ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ, МЕДИКАМЕНТ ДЛЯ ЛЕЧЕНИЯ
US6504013B1 (en) 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US6734287B1 (en) 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
EP1621209A3 (en) * 1998-11-02 2006-04-19 Resistentia Pharmaceuticals AB Vaccines based on domains of chimeric immunoglobulin E peptides
US6913749B2 (en) * 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
US6602719B1 (en) 1999-03-26 2003-08-05 Idexx Laboratories, Inc. Method and device for detecting analytes in fluids
US6511814B1 (en) 1999-03-26 2003-01-28 Idexx Laboratories, Inc. Method and device for detecting analytes in fluids
EP1195161A3 (en) * 2000-08-30 2002-07-24 Pfizer Products Inc. Anti-IgE vaccines
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
WO2003015716A2 (en) * 2001-08-13 2003-02-27 Ige Therapeutics, Inc. Immunoglobulin e vaccines and methods of use thereof
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
ATE414540T1 (de) * 2002-09-05 2008-12-15 Resistentia Pharmaceuticals Ab Impfstoffe gegen allergien
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
HUE030269T2 (en) 2006-06-26 2017-04-28 Macrogenics Inc FC RIIB-specific antibodies and methods for their use
US20080118524A1 (en) * 2006-10-20 2008-05-22 Stefan Persson Anti-IgE Vaccines
CN102245198B (zh) 2008-12-09 2016-08-17 辉瑞疫苗有限责任公司 IgE CH3肽疫苗
CN102482351B (zh) * 2009-02-25 2015-03-18 中央研究院 能与人B淋巴细胞上的mIgE结合的抗CεmX抗体
EP2942061A3 (en) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
EP2838919A4 (en) 2012-04-20 2016-03-23 Academia Sinica ANTIBLE ANTIBODIES BINDING TO THE TRANSITION BETWEEN CH4 AND C EPSILON MX DOMAINS
EP2862873B1 (en) * 2012-06-18 2020-04-29 Nippon Zenyaku Kogyo Co., Ltd. IgE PEPTIDE VACCINE
EP3017048A4 (en) * 2013-07-01 2017-05-17 University of Maryland, College Park Fc coupled compositions and methods of their use
EP3703753A4 (en) 2017-10-31 2021-08-18 Oneness Biotech Co., Ltd. TREATMENT OF IGE-MEDIATED ALLERGIC DISEASES

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8616166D0 (en) * 1986-07-02 1986-08-06 Research Corp Ltd Polypeptide competitor
GB8727045D0 (en) * 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
DE3853636T3 (de) * 1987-12-31 1999-04-08 Tanox Biosystems, Inc., Houston, Tex. Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden.
GB8910263D0 (en) * 1989-05-04 1989-06-21 Ciba Geigy Ag Monoclonal antibodies specific for an immunoglobulin isotype
GB8913737D0 (en) * 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment

Also Published As

Publication number Publication date
ES2144424T3 (es) 2000-06-16
HU218899B (hu) 2000-12-28
FI941193A (fi) 1994-03-14
ES2144424T5 (es) 2008-03-01
JP2004231663A (ja) 2004-08-19
WO1993005810A1 (en) 1993-04-01
FI107880B (fi) 2001-10-31
DE69230733D1 (de) 2000-04-06
JP3583421B2 (ja) 2004-11-04
AU2676592A (en) 1993-04-27
EP0666760B1 (en) 2000-03-01
CA2117193C (en) 2008-06-17
RU2120805C1 (ru) 1998-10-27
EP0666760A1 (en) 1995-08-16
US5653980A (en) 1997-08-05
ATE189960T1 (de) 2000-03-15
HU9400845D0 (en) 1994-06-28
DK0666760T3 (da) 2000-07-31
AU677573B2 (en) 1997-05-01
DE69230733T3 (de) 2008-05-21
EP0666760B2 (en) 2007-10-10
DE69230733T2 (de) 2000-08-03
GR3033272T3 (en) 2000-09-29
CA2117193A1 (en) 1993-04-01
FI941193A0 (fi) 1994-03-14
KR100263359B1 (ko) 2000-08-01
DK0666760T4 (da) 2008-01-21
JPH06510768A (ja) 1994-12-01
HUT69782A (en) 1995-09-28
SE9102808D0 (sv) 1991-09-26

Similar Documents

Publication Publication Date Title
SE9102808D0 (sv) Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
Jutel et al. Mechanisms of allergen specific immunotherapy–T‐cell tolerance and more
PT815235E (pt) Vacinas para peste
WO1996012794A3 (en) Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity
Jones et al. A novel Fab-based antivenom for the treatment of mass bee attacks.
Finegold et al. Immunotherapy throughout the decades: from Noon to now
DK0482089T3 (da) Fremgangsmåder til behandling af autoimmun uveoretnitis i mennesker
Braga et al. Environment and T regulatory cells in allergy
JPS63277634A (ja) アレルギーの治療およびそのための組成物
Magro et al. Eosinophilic pustular follicular reaction: a paradigm of immune dysregulation
DE69821506D1 (de) Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort
ES2319341T3 (es) Fragmentos tolerogenicos de alergenos naturales.
Classen et al. Vaccines and the risk of insulin-dependent diabetes (IDDM): potential mechanism of action
REISMAN et al. Clinical and immunological studies of venom immunotherapy
King Immunochemical studies of stinging insect venom allergens
Wu et al. Immunoblot analysis of allergens in crude mosquito extracts
Sparholt et al. The allergen specific B‐cell response during immunotherapy
Wang et al. Epicutaneous administration of hapten through patch application augments TH2 responses which can downregulate the elicitation of murine contact hypersensitivity
Ishizaka Cellular mechanisms of IgE antibody response
Ruben Recombinant DNA produced human IL-2, injected in vivo, will substitute for carrier priming of helper function in the South African clawed toad, Xenopus laevis
Axelsson et al. A case of angioneurotic oedema with a high content of non-functioning, double peaked C1 esterase inhibitor
Miura et al. Immunity to jellyfish venoms: suppression of venom-induced immune responses in ultraviolet B-irradiated mice
RU95109221A (ru) Способ интерферонотерапии ю.а.севрука
Norman Clinical experience with treatment of allergies with T cell epitope containing peptides
Cook et al. Induction of allergen-specific T cells by conjugates of N-formyl-methionyl-leucyl-phenylalanine and rye grass pollen extract

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 9102808-4

Effective date: 19940401

Format of ref document f/p: F